However, these strengths must be interpreted alongside study limitations, including future studies directly comparing liproxstatin-1 with other neuroprotective agents in primary neurons or in vivo neurodegeneration models such as APP/PS1 mice for Alzheimer’s disease and MPTP-induced Parkinsonism are critical to further validate its therapeutic potential and translational value. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.